Dublin, Ireland, October 8th 2007 - AGI Therapeutics plc (“AGI” or the “Company”) (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the presentation of Phase II clinical results of Rezular, AGI’s arverapamil (AGI-003) product, at the American College of Gastroenterology Scientific Meeting being held in Philadelphia.
